# DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs

> **NCT06329908** · EARLY_PHASE1 · RECRUITING · sponsor: **Zhen-Yu Ding** · enrollment: 20 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** LG002

## Key facts

- **NCT ID:** NCT06329908
- **Lead sponsor:** Zhen-Yu Ding
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-27
- **Primary completion:** 2024-09-30
- **Final completion:** 2026-10-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06329908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06329908, "DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06329908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*